RYR2 and catecholaminergic polymorphic ventricular tachycardia: To address the controversy regarding the possible mutation-dependent efficacy of flecainide on Ca2+ waves (Hilliard et al., 2010; Liu et al., 2011), we chose two widely published mouse models of CPVT: mice lacking calsequestrin (Casq2−/− mice) (Knollmann et al., 2006) and mice heterozygous for the RyR2-R4496C mutation (RyR2R4496C+/– mice) (Cerrone et al., 2005).